Clinical Resources

Clinical Resources for Providers

Access comprehensive clinical guidelines, protocols, and evidence-based resources for PrEP prescribing and patient care.

closeup of a young caucasian man with a simulated PrEP pill in his hand
Health Centers
Clinical Protocols
Training Materials
Quality Improvement

Evidence-Based

Guidelines based on latest clinical research and CDC recommendations

Implementation Ready

Practical tools for immediate clinical implementation

Regularly Updated

Content updated with latest clinical developments

Medication Guide

PrEP Medication Options

Comprehensive overview of FDA-approved PrEP medications including indications, contraindications, and provider resources

The PrEP is HIV prevention pill for medical concept 3d rendering
ORAL DAILY

Truvada®

Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)

Indications

  • HIV-negative adults and adolescents ≥35 kg
  • At risk through sexual activity or injection drug use
  • Receptive vaginal sex (approved for all genders)
  • Event-driven dosing (2-1-1) for MSM only

Contraindications

  • HIV-positive or unknown HIV status
  • eGFR <60 mL/min (renal impairment)
  • Signs/symptoms of acute HIV infection
  • Hypersensitivity to components

Key Considerations

  • • Generic available (cost-effective option)
  • • Monitor renal function every 3-6 months
  • • May decrease bone mineral density
  • • Safe during pregnancy/breastfeeding
Gilead Provider Portal

Manufacturer: Gilead Sciences

ORAL DAILY

Descovy®

Emtricitabine/Tenofovir Alafenamide (FTC/TAF)

Indications

  • HIV-negative adults and adolescents ≥35 kg
  • At risk through sexual activity (except receptive vaginal sex)
  • Preferred for patients with renal concerns
  • Preferred for patients with bone density concerns

Contraindications

  • HIV-positive or unknown HIV status
  • eGFR <30 mL/min (severe renal impairment)
  • NOT approved for receptive vaginal sex
  • NOT approved for injection drug use risk

Key Considerations

  • • Better renal and bone safety profile than TDF
  • • No generic available (brand only)
  • • May increase lipid levels
  • • Limited data in pregnancy
Gilead Provider Portal

Manufacturer: Gilead Sciences

INJECTABLE

Apretude®

Cabotegravir Extended-Release Injectable (CAB-LA)

Indications

  • HIV-negative adults and adolescents ≥35 kg
  • At risk through sexual activity
  • Administered every 2 months (after initiation)
  • Ideal for patients with adherence challenges

Contraindications

  • HIV-positive or unknown HIV status
  • Previous hypersensitivity to cabotegravir
  • Co-administration with rifampin, rifapentine, carbamazepine, phenobarbital, phenytoin
  • NOT approved for injection drug use risk

Key Considerations

  • • Initiate with oral lead-in or 2 injections 1 month apart
  • • IM gluteal injection only
  • • Long drug tail if discontinued - continue monitoring
  • • Injection site reactions common
ViiV Healthcare Provider Portal

Manufacturer: ViiV Healthcare

NEW
TWICE YEARLY

Yetugo®

Lenacapavir Injectable for PrEP (LEN)

Indications

  • HIV-negative adults and adolescents at risk
  • At risk through sexual activity
  • Administered every 6 months (twice yearly)
  • Longest-acting PrEP option available

Contraindications

  • HIV-positive or unknown HIV status
  • Co-administration with strong CYP3A inducers (rifampin, carbamazepine, phenytoin)
  • Hypersensitivity to lenacapavir
  • Use caution with strong CYP3A inhibitors

Key Considerations

  • • Subcutaneous injection (not IM like Apretude)
  • • Demonstrated 100% efficacy in PURPOSE 1 trial (cisgender women)
  • • First capsid inhibitor approved for PrEP
  • • Long drug tail requires continued monitoring if discontinued
Gilead Provider Portal

Manufacturer: Gilead Sciences

Quick Comparison Chart

Side-by-side comparison of PrEP medication options

Feature Truvada (TDF/FTC) Descovy (TAF/FTC) Apretude (CAB-LA) Yetugo (LEN)
Administration Oral daily Oral daily IM injection q2months Subcutaneous q6months
Receptive Vaginal Sex Yes No Yes Yes
Receptive Anal Sex Yes Yes Yes Yes
Injection Drug Use Yes No No No
Event-Driven (2-1-1) MSM only No No No
Renal Safety Monitor closely Improved No concerns No concerns
Generic Available Yes No No No
Pregnancy Data Extensive Limited Limited Limited

HIVinfo.nih.gov

National Institutes of Health

Comprehensive HIV/AIDS information, treatment guidelines, and clinical resources from NIH.

Visit Site

WHO HIV/AIDS Fact Sheet

World Health Organization

Global HIV/AIDS statistics, key facts, and WHO recommendations for prevention and treatment.

View Fact Sheet

UNAIDS Fact Sheet

Joint United Nations Programme

Global HIV statistics, epidemic updates, and resources from the leading UN agency on HIV/AIDS.

View Resources

CDC Clinical Guidelines

Official Recommendations

Latest CDC guidelines for PrEP prescribing and clinical practice.

View Guidelines

Important Notice

This information is intended as a clinical reference for healthcare providers. Always consult the full prescribing information and current CDC guidelines for complete details. Medication selection should be based on individual patient characteristics, preferences, and clinical judgment. Links to manufacturer websites are provided for provider convenience and do not constitute endorsement.

Adolescent Resources

PrEP 4 Teens

Specialized resources for prescribing PrEP to adolescent patients, including clinical guidance, consent considerations, and age-appropriate patient education materials.

Visit PrEP4Teens.com

Clinical Guidance

Evidence-based guidelines for prescribing PrEP to adolescents ages 13-17, including dosing, monitoring, and follow-up protocols.

  • • Age-appropriate dosing
  • • Lab monitoring schedules
  • • Follow-up frequency

Consent & Confidentiality

Illinois-specific information on minor consent laws, confidentiality requirements, and billing considerations for adolescent patients.

  • • Minor consent laws in IL
  • • Confidential billing practices
  • • Parent/guardian considerations

Teen-Friendly Materials

Age-appropriate educational resources designed to engage adolescent patients and support informed decision-making.

  • • Youth-focused brochures
  • • Conversation starters
  • • Adherence support tools

Key Considerations for Adolescent PrEP

Eligibility

PrEP is FDA-approved for adolescents weighing at least 35kg. Assessment should include sexual history, risk factors, and readiness for daily medication adherence.

Communication

Use developmentally appropriate language and create a safe, non-judgmental environment for discussing sexual health with teen patients.

Support Systems

Consider involving trusted adults when appropriate while respecting the adolescent's right to confidential care under Illinois law.

Follow-Up Care

Regular check-ins to assess adherence, side effects, ongoing risk, and provide continued support for healthy decision-making.